by Plus Therapeutics | Jul 8, 2025 | LM
Plus Therapeutics is pleased to announce that the first patients have been treated in the ReSPECT-LM dose optimization clinical trial, evaluating REYOBIQ™ (rhenium Re 186 obisbemeda) for the treatment of leptomeningeal metastases (LM)—a devastating and often...
by Plus Therapeutics | Jun 30, 2025 | LM
Plus Therapeutics is pleased to announce the initiation of the ReSPECT-LM dose optimization clinical trial for REYOBIQ™ (rhenium Re 186 obisbemeda), a radiotherapeutic designed to target and treat leptomeningeal metastases (LM)—a devastating complication of metastatic...
by Plus Therapeutics | Jun 5, 2025 | LM
June Is Brain and Spine Metastasis Awareness Month: Spotlight on Leptomeningeal Metastases and New Treatment Approaches Following Brain Cancer Awareness Month, June marks Brain and Spine Metastasis Awareness Month, a critical time to raise awareness about the...
by Plus Therapeutics | May 14, 2025 | LM
New Data on REYOBIQ™ for Leptomeningeal Metastases Presented at the NMN Conference! Plus Therapeutics is pleased to announce that new clinical data on its lead investigational therapy, REYOBIQ™ (rhenium Re 186 obisbemeda), was presented at the Nuclear Medicine and...
by Plus Therapeutics | May 1, 2025 | GBM, LM, PBC, Uncategorized
Honoring Brain Cancer Awareness Month: Advancing Research, Raising Voices, and Recruiting for Clinical Trials May is Brain Cancer Awareness Month! A time dedicated to elevating the voices of patients, caregivers, and advocates affected by brain tumors. At Plus...
by Plus Therapeutics | Apr 15, 2025 | LM
Plus Therapeutics to Present New REYOBIQ™ Clinical Data at Nuclear Medicine Symposium 2025 We’re excited to announce that Plus Therapeutics will present new data on our lead radiotherapeutic compound, REYOBIQ™ (rhenium Re186 obisbemeda), at the upcoming Nuclear...
Recent Comments